Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
作者:
主题词
动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞系, 肿瘤(Cell Line, Tumor);药物协同作用(Drug Synergism);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);HL-60细胞(HL-60 Cells);组蛋白类(Histones);人类(Humans);羟肟酸类(Hydroxamic Acids);凋亡抑制蛋白质类(Inhibitor of Apoptosis Proteins);K562细胞(K562 Cells);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);小鼠(Mice);微管相关蛋白质类(Microtubule-Associated Proteins);突变(Mutation);肿瘤蛋白质类(Neoplasm Proteins);哌嗪类(Piperazines)
DOI
10.1158/1078-0432.CCR-08-0721
PMID
18829489
发布时间
2022-06-01
- 浏览113

Clinical cancer research
6106-15页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文